133 related articles for article (PubMed ID: 25326244)
1. Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
Praschberger M; Haider K; Cornelius C; Schitegg M; Sturm B; Goldenberg H; Scheiber-Mojdehkar B
Biometals; 2015 Feb; 28(1):35-50. PubMed ID: 25326244
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
Connor JR; Zhang X; Nixon AM; Webb B; Perno JR
PLoS One; 2015; 10(5):e0125272. PubMed ID: 25973894
[TBL] [Abstract][Full Text] [Related]
3. In vitro studies of ferric carboxymaltose on placental permeability using the dual perfusion model of human placenta.
Malek A
Arzneimittelforschung; 2010; 60(6a):354-61. PubMed ID: 20648927
[TBL] [Abstract][Full Text] [Related]
4. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
Fell LH; Seiler-Mußler S; Sellier AB; Rotter B; Winter P; Sester M; Fliser D; Heine GH; Zawada AM
Nephrol Dial Transplant; 2016 Nov; 31(11):1835-1845. PubMed ID: 27190361
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron.
Sturm B; Laggner H; Ternes N; Goldenberg H; Scheiber-Mojdehkar B
Kidney Int; 2005 Mar; 67(3):1161-70. PubMed ID: 15698458
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
Praschberger M; Cornelius C; Schitegg M; Goldenberg H; Scheiber-Mojdehkar B; Sturm B
Pharm Dev Technol; 2015 Mar; 20(2):176-82. PubMed ID: 24219061
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
8. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
Funk F; Ryle P; Canclini C; Neiser S; Geisser P
Arzneimittelforschung; 2010; 60(6a):345-53. PubMed ID: 20648926
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound.
Toblli JE; Cao G; Rico L; Angerosa M
Drug Des Devel Ther; 2017; 11():3401-3412. PubMed ID: 29238166
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
13. The effect of ascorbic acid and ferric ammonium citrate on iron uptake and storage in lens epithelial cells.
Goralska M; Harned J; Fleisher LN; McGahan MC
Exp Eye Res; 1998 Jun; 66(6):687-97. PubMed ID: 9657901
[TBL] [Abstract][Full Text] [Related]
14. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
15. In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress.
Sturm B; Steinkellner H; Ternes N; Goldenberg H; Scheiber-Mojdehkar B
Arzneimittelforschung; 2010; 60(7):459-65. PubMed ID: 20712137
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.
Allen RP; Adler CH; Du W; Butcher A; Bregman DB; Earley CJ
Sleep Med; 2011 Oct; 12(9):906-13. PubMed ID: 21978726
[TBL] [Abstract][Full Text] [Related]
17. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
18. Ferric carboxymaltose reduces the number of red blood cell units transfused and allows transfusion independence to be obtained in patients with iron deficiency anemia secondary to gastrointestinal chronic blood loss.
Salvadori U; Sandri M; Melli C; Polese F; Simeoni M; Capelli S; Al-Khaffaf A
Transfusion; 2016 Nov; 56(11):2720-2726. PubMed ID: 27600706
[TBL] [Abstract][Full Text] [Related]
19. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
Evstatiev R; Alexeeva O; Bokemeyer B; Chopey I; Felder M; Gudehus M; Iqbal T; Khalif I; Marteau P; Stein J; Gasche C;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):269-77. PubMed ID: 23078888
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
